Imvaq Therapeutics is an innovative cancer immunotherapy company founded by world-leading researchers at Memorial Sloan Kettering Cancer Center. The company is developing novel viral-based, armed immune-stimulating therapies to treat a variety of metastatic solid tumors including skin cancers, sarcoma, as well as hard-to-treat tumors such as triple-negative breast cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/29/20 | $15,000,000 | Series B |
Hanne Capital | undisclosed |
